265108-36-9

Basic information

• Product Name: Cyclohexanecarboxaldehyde, 4,4-difluoro- (9CI)
• Synonyms: Cyclohexanecarboxaldehyde, 4,4-difluoro- (9CI);4,4-Difluoro Cyclohexanecarboxaldehyde;4,4-Difluoro-cyclohexanecarbaldehyde;4,4-difluorocyclohexane-1-carbaldehyde;Cyclohexanecarboxaldehyde, 4,4-difluoro-
• CAS NO: 265108-36-9
• Molecular Formula: C₇H₁₀F₂O
• Molecular Weight: 148.1505064
• Product Categories: HALIDE;ALDEHYDE
• Mol File: 265108-36-9.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 165 °C at 760 mmHg
• Flash Point: 59 °C
• Appearance: /
• Density: 1.1 g/cm³
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: Cyclohexanecarboxaldehyde, 4,4-difluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarboxaldehyde, 4,4-difluoro- (9CI)(265108-36-9)
• EPA Substance Registry System: Cyclohexanecarboxaldehyde, 4,4-difluoro- (9CI)(265108-36-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 265108-36-9(Hazardous Substances Data)

Usage

Uses

4,4-Difluorocyclohexanecarbaldehyde is used in the preparation of heteroaryl acid derivative and methods for treating oxalate-related diseases.

Upstream product

• 178312-48-6 (4,4-difluorocyclohexyl)methanol 
• 121629-14-9 methyl 4,4-difluorocyclohexane-1-carboxylate 
• 122665-97-8 4,4-difluorocyclohexanecarboxylic acid 
• 3618-04-0 4-hydroxycyclohexyl carboxylic acid ethyl ester 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 178312-47-5 ethyl 4,4-difluorocyclohexane-1-carboxylate 
• 917383-03-0 4,4-difluoro-N-methoxy-N-methylcyclohexane-1-carboxamide 
• 394-02-5 5-fluoro-2-nitrobenzoyl chloride 

Downstream Products

• 1156469-52-1 C₉H₁₄F₂O 
• 1427058-51-2 tert-butyl N-{1-[(4,4-difluorocyclohexyl)methyl]piperidin-4-yl}carbamate 
• 1354495-70-7 (-)-(5S)-4-(4,4-difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-5-[(4-methoxybenzyl)oxy]-7,7-dimethyl-2-(piperidin-4-yl)-5,6,7,8-tetrahydroquinoline 

Relevant articles and documents

Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies

The COVID-19 pandemic is having a major impact on public health worldwide, and there is an urgent need for the creation of an armamentarium of effective therapeutics, including vaccines, biologics, and small-molecule therapeutics, to combat SARS-CoV-2 and emerging variants. Inspection of the virus life cycle reveals multiple viral- and host-based choke points that can be exploited to combat the virus. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for therapeutic intervention, and the design of inhibitors of the protease may lead to the emergence of effective SARS-CoV-2-specific antivirals. We describe herein the results of our studies related to the application of X-ray crystallography, the Thorpe–Ingold effect, deuteration, and stereochemistry in the design of highly potent and nontoxic inhibitors of SARS-CoV-2 3CLpro.

COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.

CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS

The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as well as pharmaceutical compositions containing such compounds. The compounds are useful in treating diseases and conditions mediated by TEAD, such as cancer.